US 2019/0314380 A1 · DACTINOMYCIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA

Abstract

The disclosure provides a method for treating NPM1-mutated acute myeloid leukemia (AML) by administration of a composition comprising dactinomycin.

Claims30

Dependent claims

A method for treating acute myeloid leukemia (AML) in a subject in need thereof comprising administering to the subject a therapeutically-effective amount of a composition comprising Dactinomycin, wherein the composition further comprises a pharmaceutically acceptable carrier.

Dependencies are inferred from the claim text.

Facts

Application

16/418,374Filed 21 May 2019

Priority

14 Sep 2015

Published

17 Oct 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification5 codes

A61K 31/538
1,4-Oxazines, e.g. morpholine: ortho- or peri-condensed with carbocyclic ring systems
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61P 35/02
Antineoplastic agents: specific for leukemia
A61K
Medicines and medical preparations

Family

Application62/218,433Us provisional application · filed 14 Sep 2015

Application15/759,442Continuation · filed 12 Mar 2018

Application16/418,374Continuation

US 10,335,416 B2Related patent

US 11,337,983 B2Related patent

US 2018/0207168 A1Published application

US 2019/0314380 A1This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

The disclosure provides a method for treating NPM1-mutated acute myeloid leukemia (AML) by administration of a composition comprising dactinomycin.

Dactinomycin compositions and methods for the treatment of acute myeloid leukemia

Life of this patent

Abstract

Claims30

Dactinomycin compositions and methods for the treatment of acute myeloid leukemia

Life of this patent

Abstract

Claims30